Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study.
Saved in:
| Title: | Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. |
|---|---|
| Authors: | Nooka, Ajay K.1 (AUTHOR) anooka@emory.edu, Rodriguez, Cesar2 (AUTHOR), Mateos, María Victoria3 (AUTHOR), Manier, Salomon4 (AUTHOR), Chastain, Katherine5 (AUTHOR), Banerjee, Arnob6 (AUTHOR), Kobos, Rachel5 (AUTHOR), Qi, Keqin7 (AUTHOR), Verona, Raluca6 (AUTHOR), Doyle, Margaret8 (AUTHOR), Martin, Thomas G.9 (AUTHOR), van de Donk, Niels W. C. J.10 (AUTHOR) |
| Source: | Cancer (0008543X). Mar2024, Vol. 130 Issue 6, p886-900. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 0008543X |
|---|---|
| DOI: | 10.1002/cncr.35107 |
